TCT-87 Targeting systolic anterior motion and left ventricular outflow tract obstruction in hypertrophic obstructed cardiomyopathy with a MitraClip  by Schaefer, Ulrich et al.
TUESDAY, OCTOBER 29, 2013, 1:00 PM–3:15 PM www.jacctctabstracts2013.com
O
R
A
L
Sp ¼ <0.001). Reduction in LV volumes was seen in both functional and degenerative
MR subtypes. LA volumes decreased an average of 29 ml (p ¼0.009) after successful
SR, but LA volumes were only reduced signiﬁcantly in the PR group when residual
MR severity was  1+ (reduction of 14 ml, p¼0.0016). (Table 1).
Conclusions: Favorable LV remodeling occurred after successful PR, however
improvements were less robust compared to SR at 4 years. LA volumes improved
signiﬁcantly after successful SR, but only after PR when residual MR was 1+.
Further study should inform whether the degree of reverse remodeling impacts long-
term clinical outcomes and MitraClip durability.P
er
cu
ta
ne
ou
s
(N
)
S
ur
g
ic
al
(N
)
M
R
S
ev
er
it
y
at
4
8
M
on
th
s
V
ar
ia
bl
e
B
as
el
in
e
4
8
m
on
th
s
C
ha
ng
e
p
va
lu
e
B
as
el
in
e
4
8
m
on
th
s
C
ha
ng
e
p
va
lu
e
B
et
w
ee
n
g
ro
up
p
va
lu
e
All £2+ LVEDVI
(ml/m2)
15033
(61)
12134
(59)
-2929 <0.001 16247
(39)
11342
(35)
-5132 <0.001 <0.001
LVESVI
(ml/m2)
6122
(61)
5224
(59)
-819 0.0018 6128
(39)
4929
(35)
-1317 <0.001 0.2
LA
volume
(ml)
7824
(59)
7326
(59)
-523 0.11 8133
(37)
5220
(33)
-2822 <0.001 <0.001
LVEF% 609.0
(61)
589
(59)
-28 0.06 639
(39)
5811
(35)
-49 0.009 0.2
All £1+ LVEDVI
(ml/m2)
15135
(28)
11426
(28)
-3426 <0.001 15844
(35)
10633
(31)
-5332 <0.001 0.019
LVESVI
(ml/m2)
6425
(28)
4817
(28)
-1517 <0.001 5620
(35)
4422
(31)
-1316 <0.001 0.61
LA
volume
(ml)
7920
(28)
6720
(27)
-1420 0.0016 8134
(33)
4919
(31)
-2921 <0.001 0.009
LVEF % 5811
(28)
5810
(28)
110 0.72 656
(35)
6010
(29)
-510 0.0085 0.035
basal post ES post nitro
basal after
Clip
Post ES
after Clip
average Peak gradient
(mmHg)
5627 13423 8428 106 229
patient #1 PP-gradient 36.0 136.0 55.0 3.0 19.0
patient #2 PP-gradient 75.0 150.0 120.0 7.0 35.0
patient #3 PP-gradient 84.0 150.0 90.0 13.0 16.0
patient #4 PP-gradient 30.0 100.0 70.0 17.0 18.0
average Mean gradient
(mmHg)
4113 8933 6121 135 217
SAM ++ +++ +++ 0 +
MR (grade) 2.60.25 3.00 3.00 0.50.4 0.630.25
patient #1 mean
transmitral gradient
3.0 n.a. n.a. 5.0 n.a.
patient #2 mean
transmitral gradient
2.0 n.a. n.a. 3.0 n.a.
patient #3 mean
transmitral gradient
3.0 n.a. n.a. 3.0 n.a.
patient #4 mean
transmitral gradient
3.0 n.a. n.a. 6.0 n.a.TCT-86
The 2011-12 Pilot European Sentinel Registry of Percutaneous Edge-to-Edge
Mitral Valve Repair: In-hospital results and mid-term follow up of 587 patients
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Klaus Tiroch9, Olaf Franzen10
1HemoLeon, Fundación Investigación Sanitaria en León, Leon, Leon, 2University
Hospital Bonn, Bonn, Germany, 3University Heart Center Hamburg, Hamburg,
Hamburg, 4Karolinska Hospital, Stocholm, Sweden, 5Imperial College London,
London, United Kingdom, 6royal brompton hospital, London, United Kingdom,
7University of Pisa, Pisa, Italy, 8Ferraroto Hospital, Catania, Italy, 9HELIOS
Klinkum, Wuppertal, Germany, 10Rigshospitalet Copenhagen, Copenhagen, Denmark
Background: Edge-to-edge percutaneous mitral valve repair has emerged as an
alternative to surgery in high-risk patients. However, data with regard to its safety and
efﬁcacy in real-world patients are still scarce. The aim of this prospective multina-
tional registry is to present a real-world overview of MitraClip use focusing on patient
characteristics, clinical indication, technique, in-hospital and mid-term outcome.
Methods: The Transcatheter Valve Treatment Sentinel Pilot Registry is a prospective
independent consecutive collection of individual patient data entered into a web-based
case record form (CRF).
Results: A total of 587 patients (mean age 74.79.5 years, 64.1 % male) underwent
MitraClip implantation between January 2011 and December 2012 in 25 centres of 8
European countries. The prevalent etiology was functional MR (FMR; 414 patients,
70.5%) while 150 patients (25.5%) were diagnosed as having degenerative MR
(DMR), with the remaining patients (23, 4.0%) classiﬁed as mixed aetiology or MR of
unknown origin.Logistic EuroSCORE was high (19.916.0%). Successful deploy-
ment of at least 1 clip was achieved in 95.9% of patients, with a trend to higher
implantation success in the FMR group (p¼0.087). Acute procedural success was high
(97.3%) and equivalent between groups (p¼1.000). One clip was implanted in the
majority of cases (60.7%), two clips were implanted in 35.9% of cases and a small
minority received 3 or more clips (3.4%). Patients with DMR tended to receive
a greater number of clips (2 clips implanted in 43.5% of patients with DMR vs.
37.4% of patients with FMR, p¼0.191) than those with functional mitral regurgitation.
Echocardiograms prior to discharge showed a marked reduction in mitral insufﬁciency
to 2+ in 98.2% of patients, with equivalence between groups. In-hospital mortality
was low (2.0%) and without signiﬁcant differences between groups, although DMR
group had a trend to higher mortality. Clinical and echo follow-up data at 6-12 month
will be available at the time of presentation.B28 JACC Vol 62/18/Suppl B j October 27–November 1, 2013Conclusions: this truly independent and contemporary registry of MitraClip
implantation shows that the technique is effective and is associated with low
complication rate.
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Targeting systolic anterior motion and left ventricular outﬂow tract obstruction
in hypertrophic obstructed cardiomyopathy with a MitraClip
Ulrich Schaefer1, Christian Frerker1, Felix Kreidel1, Karl-Heinz Kuck1
1Asclepios Clinics St. Georg, Hamburg, Germany
Background: Hypertrophic obstructive cardiomyopathy (HOCM) with left ventric-
ular outﬂow tract obstruction frequently involves a systolic anterior motion (SAM) of
the anterior mitral leaﬂet. We hypothesized, that SAM could be a new target for
MitraClip therapy.
Methods: Four patients with HOCM were chosen for MitraClip therapy, due to
signiﬁcant SAM with subsequent mitral regurgitation. Invasive hemodynamic studies
(right heart catheterization, simultaneous transaortic pressure recording, administra-
tion of nitroglycerin) before and after MitraClip implantation in addition to 6 weeks
follow-up were performed.
Results: MitraClip implantation was successfully performed with signiﬁcant reduc-
tion of mitral regurgitation and SAM in all patients. Basal peak gradients (before Clip:
5627 mmHg; after clip: 106 mmHg) as well as provoked pressure gradients
(before clip: 13423 mmHg; after clip: 218 mmHg) were signiﬁcantly reduced after
MitraClip. Right heart catheterization data did not reveal major changes. At 6-weeks
follow-up, all patients presented in a persistent improved clinical state (NYHA class I-
II) with insigniﬁcant residual MR and continuously reduced LVOT gradients.
Conclusions: This is the ﬁrst catheter-based study targeting primarily a SAM in
HOCM to reduce LVOT obstruction. The results prove the concept, that SAM is more
than an epiphenomenon in HOCM. Thus, SAM-induced obstruction might be
a valuable target for the MitraClip.TCT-88
Outcomes of Cardiac Surgery are Preserved Following the MitraClip Procedure.
Alfredo Trento1, Wen Loong Yeow1, Takashi Matsumoto1, Asma Hussaini1,
Swaminatha V. Gurudevan1, Takahiro Shiota1, Saibal Kar1
1Cedars-Sinai Medical Center, Los Angeles, CA
Background: Transcatheter mitral valve repair with the MitraClip is a safe procedure
for severe mitral regurgitation (MR). A reported higher mitral valve replacement rate
following the MitraClip resulted in an overstated complexity of subsequent surgery
and its implications on patient outcomes. This study will review the outcomes of
cardiac surgery following MitraClip procedure.
Methods: Of the 157 consecutive patients that underwent the MitraClip procedure in
our center, 16 (10%) required cardiac surgery. These patients (mean 6712 years old,
7 (44%) women) with Society of Thoracic Surgeons mortality score of 0.5 to 17.1%
were reviewed in regards to their operative details and outcomes. The mean implant
duration was 12.5 months (range 14 days to 75 months).
Results: No patient required urgent cardiac surgery for failed MitraClip procedure. Of
the 9 patients with degenerative MR, 8 were repaired and 1 had a replacement for
MitraClip endocarditis. Robotic assisted repair occurred in one patient that had no
implanted clip whilst 2 had one clip, and 3 had two clips; the implant duration ranged
from 2.5 months to 6.3 years. Of the 7 patients with functional MR, 5 had replacement
and 2 required heart transplantation for severe heart failure. There was no operativej TCT Abstracts/ORAL/Percutaneous Treatment of Mitral Valve Disease
